184 related articles for article (PubMed ID: 34098836)
1. Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
Shi D; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
Leuk Lymphoma; 2021 Nov; 62(11):2703-2715. PubMed ID: 34098836
[TBL] [Abstract][Full Text] [Related]
2. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668
[No Abstract] [Full Text] [Related]
3. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
4. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
5. Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
Bao M; Zhang M; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
Acta Haematol; 2023; 146(4):293-306. PubMed ID: 36812897
[TBL] [Abstract][Full Text] [Related]
6. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
7. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
8. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
11. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
13. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
[TBL] [Abstract][Full Text] [Related]
14. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Bose P; Verstovsek S
Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
[TBL] [Abstract][Full Text] [Related]
15. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada.
Bankar A; Zhao H; Iqbal J; Coxford R; Cheung MC; Mozessohn L; Earle CC; Gupta V
Leuk Lymphoma; 2020 Aug; 61(8):1908-1919. PubMed ID: 32323602
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
18. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms.
Krečak I; Peran N; Lapić I; Gverić-Krečak V; Krečak F; Rončević P; Duraković N
Wien Klin Wochenschr; 2021 Jan; 133(1-2):62-64. PubMed ID: 32300883
[TBL] [Abstract][Full Text] [Related]
19. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]